Bone
5. Nov 2005
Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo
Autosomal dominant osteopetrosis type I (ADOI) is presumably caused by gain-of-function mutations in the LRP5 gene. Patients with a T253I mutation in LRP5 have a high bone mass phenotype, characterized by increased mineralizing surface index but abnormally low numbers of small osteoclasts. To invest…
Read the publication
Journal:
Authors:
- Henriksen K,
- Gram J,
- Høegh-Andersen P,
- Jemtland R,
- Ueland T,
- Dziegiel MH,
- Schaller S,
- Bollerslev J,
- Karsdal MA,
Bone
18. Oct 2005
The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment
Chloride ions play a major role in osteoclast biology and bone homeostasis. In addition to its general cellular roles, chloride is involved in the specific bone resorption activity of osteoclasts. The chloride channel ClC-7 has been shown to be mandatory for bone resorption. It is necessary for the …
Read the publication
Journal:
Authors:
- Schaller S,
- Henriksen K,
- Sørensen MG,
- Karsdal MA,
Rheumatology, Osteoarthritis
7. Jul 2005
Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis
OBJECTIVE:
To assess the efficacy of 3 months of oral salmon calcitonin (sCT) on cartilage degradation as estimated by the changes in the urinary excretion of C-terminal telopeptide of collagen type II (CTX-II), and to investigate whether the response of oral sCT to urinary CTX-II depends on the ba…
Read the publication
Journal:
Authors:
- Bagger YZ,
- Tankó LB,
- Alexandersen P,
- Karsdal MA,
- Olson M,
- Mindeholm L,
- Azria M,
- Christiansen C,
Rheumatology, Osteoarthritis
1. Jul 2005
The clinical potential of estrogen for the prevention of osteoarthritis: what is known and what needs to be done?
Osteoarthritis (OA) remains a major epidemiological problem worldwide. The lack of established chondroprotective agents limits the clinical management of this disease to relief of symptoms, such as pain and joint stiffness. The marked increase in the prevalence and incidence of OA among women after …
Read the publication
Journal:
Authors:
- Tankó LB,
- Karsdal MA,
- Christiansen C,
Bone
2. Jun 2005
In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist
Although our approach to the clinical management of osteoporosis (OP) and degenerative joint diseases (DJD)-major causes of disability and morbidity in the elderly-has greatly advanced in the past decades, curative treatments that could bring ultimate solutions have yet to be found or developed. Eff…
Read the publication
Journal:
Authors:
- Schaller S,
- Henriksen K,
- Hoegh-Andersen P,
- Søndergaard BC,
- Sumer EU,
- Tankó LB,
- Qvist P,
- Karsdal MA,
Bone
5. Feb 2005
Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption
Patients with defective osteoclastic acidification have increased numbers of osteoclasts, with decreased resorption, but bone formation that remains unchanged. We demonstrate that osteoclast survival is increased when acidification is impaired, and that impairment of acidification results in inhibit…
Read the publication
Journal:
Authors:
- Karsdal MA,
- Henriksen K,
- Sørensen MG,
- Gram J,
- Schaller S,
- Dziegiel MH,
- Heegaard AM,
- Christophersen P,
- Martin TJ,
- Christiansen C,
- Bollerslev J,